Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Derazantinib

            Therapeutic Area: Oncology Product Name: BAL087

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 10, 2021

            Details:

            Clinical proof of concept achieved for derazantinib monotherapy in FGFR2 gene fusion-positive iCCA. Derazantinib has shown a well manageable safety profile.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Camidanlumab tesirine

            Therapeutic Area: Oncology Product Name: Cami

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 04, 2021

            Details:

            Camidanlumab tesirine (Cami, formerly ADCT-301) is an antibody drug conjugate (ADC) comprised of a monoclonal antibody that binds to CD25 (HuMax®-TAC, licensed from Genmab A/S), conjugated to the pyrrolobenzodiazepine (PBD) dimer payload, tesirine.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Efineptakin alfa,Atezolizumab

            Therapeutic Area: Oncology Product Name: NT-I7

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: NeoImmuneTech

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration October 21, 2020

            Details:

            This new master agreement will focus initially on a Phase 2 trial in previously untreated, PD-L1-expressing, locally advanced or metastatic non-small cell lung cancer patients, with the goal to evaluate anti-tumor efficacy and safety of the NT-I7 and atezolizumab combination.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tenalisib

            Therapeutic Area: Oncology Product Name: RP6530

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Curon Biopharmaceutical

            Deal Size: $149.5 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement October 12, 2020

            Details:

            Curon obtains the exclusive development and commercialization rights of Tenalisib for Greater China across all oncology indications, and will lead the clinical development in that territory.